{"id":56555,"date":"2026-02-06T22:30:29","date_gmt":"2026-02-06T14:30:29","guid":{"rendered":"https:\/\/flcube.com\/?p=56555"},"modified":"2026-02-06T22:30:30","modified_gmt":"2026-02-06T14:30:30","slug":"insight-lifetech-debuts-on-shanghai-star-market-with-3-billion-valuation-breaking-import-monopoly-in-cardiovascular-imaging","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56555","title":{"rendered":"Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging"},"content":{"rendered":"\n<p><strong>Insight Lifetech<\/strong>, a <strong>Qiming Venture Partners<\/strong>\u2011backed innovative medical device manufacturer, has <strong>listed on the Shanghai Stock Exchange&#8217;s STAR Market<\/strong> (<strong><a href=\"https:\/\/www.google.com\/finance\/quote\/688712:SHA\">SHA: 688712<\/a><\/strong>), pricing its IPO at <strong>RMB\u202f17.52 (USD\u202f2.52)<\/strong> per share and achieving a <strong>market capitalization of RMB\u202f20.98 billion (USD\u202f3.02 billion)<\/strong> based on its opening price of <strong>RMB\u202f50.31 (USD\u202f7.24)<\/strong>. The debut marks a milestone for China\u2019s domestic precision cardiovascular interventional technology sector.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-overview\">Transaction Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Insight Lifetech<\/td><\/tr><tr><td><strong>Listing Venue<\/strong><\/td><td>Shanghai Stock Exchange STAR Market<\/td><\/tr><tr><td><strong>Ticker<\/strong><\/td><td>688712.SH<\/td><\/tr><tr><td><strong>IPO Price<\/strong><\/td><td>RMB\u202f17.52 (USD\u202f2.52) per share<\/td><\/tr><tr><td><strong>Opening Price<\/strong><\/td><td>RMB\u202f50.31 (USD\u202f7.24) per share<\/td><\/tr><tr><td><strong>Market Cap at Open<\/strong><\/td><td>RMB\u202f20.98 billion (USD\u202f3.02 billion)<\/td><\/tr><tr><td><strong>Lead Investor<\/strong><\/td><td>Qiming Venture Partners (6%+ pre\u2011IPO stake)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-platform-amp-market-position\">Technology Platform &amp; Market Position<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Founded:<\/strong> 2015<\/li>\n\n\n\n<li><strong>Specialization:<\/strong> <strong>Precision cardiovascular interventional solutions<\/strong><\/li>\n\n\n\n<li><strong>Breakthrough Achievement:<\/strong> <strong>China\u2019s first domestic manufacturer<\/strong> to offer comprehensive <strong>intravascular functional imaging portfolio<\/strong>, specifically:<\/li>\n\n\n\n<li><strong>Fractional Flow Reserve (FFR)<\/strong> \u2013 Hemodynamic assessment for coronary lesion severity<\/li>\n\n\n\n<li><strong>Intravascular Ultrasound (IVUS)<\/strong> \u2013 High\u2011resolution intracoronary imaging for plaque characterization<\/li>\n\n\n\n<li><strong>Strategic Impact:<\/strong> Breaks <strong>foreign import monopoly<\/strong> in cardiovascular diagnostic catheters, addressing critical supply\u2011chain security and cost\u2011reduction priorities in China\u2019s healthcare system<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-investor-background-amp-capital-structure\">Investor Background &amp; Capital Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Financing Round<\/th><th>Lead Investor<\/th><th>Strategic Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>Series C (2020)<\/strong><\/td><td>Qiming Venture Partners<\/td><td>Initial institutional anchor investment<\/td><\/tr><tr><td><strong>Series D<\/strong><\/td><td>Qiming Venture Partners (continued)<\/td><td>Growth capital for regulatory approvals and manufacturing scale\u2011up<\/td><\/tr><tr><td><strong>Pre\u2011IPO Stake<\/strong><\/td><td>Qiming Venture Partners (&gt;6%)<\/td><td>Major institutional shareholder supporting public market transition<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-competitive-landscape\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Cardiovascular Imaging Market:<\/strong> China\u2019s <strong>FFR and IVUS market<\/strong> has been dominated by <strong>Abbott, Boston Scientific, and Philips<\/strong>, with imported devices commanding premium pricing and creating procurement bottlenecks.<\/li>\n\n\n\n<li><strong>Import Substitution Policy:<\/strong> Insight Lifetech\u2019s domestic manufacturing aligns with <strong>&#8220;Made in China 2025&#8221;<\/strong> healthcare technology localization mandates, positioning the company for <strong>hospital procurement preferences<\/strong> and potential national volume\u2011based purchasing program inclusion.<\/li>\n\n\n\n<li><strong>STAR Market Premium:<\/strong> The <strong>187% opening pop<\/strong> (RMB\u202f17.52 to RMB\u202f50.31) reflects investor enthusiasm for <strong>medical device innovation<\/strong> and <strong>cardiovascular precision medicine<\/strong> plays, despite broader Hong Kong\/China biotech IPO volatility.<\/li>\n\n\n\n<li><strong>Qiming Validation:<\/strong> Qiming Venture Partners\u2019 sustained backing through Series C, D, and IPO underscores <strong>venture confidence in domestic medtech<\/strong> and provides governance continuity as Insight scales commercial operations.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-outlook\">Strategic Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Priority<\/th><th>Execution Plan<\/th><\/tr><\/thead><tbody><tr><td><strong>Manufacturing Scale<\/strong><\/td><td>Expand production capacity to meet domestic hospital demand and reduce import dependency<\/td><\/tr><tr><td><strong>Regulatory Expansion<\/strong><\/td><td>Leverage NMPA approvals for FFR\/IVUS to pursue Southeast Asian and Belt\u2011and\u2011Road market registrations<\/td><\/tr><tr><td><strong>Product Pipeline<\/strong><\/td><td>Develop next\u2011generation integrated FFR\u2011IVUS consoles and AI\u2011powered image analysis software<\/td><\/tr><tr><td><strong>Market Share Capture<\/strong><\/td><td>Target tier\u20111 and tier\u20112 city hospitals with competitive pricing vs. Abbott\/Boston Scientific<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Insight Lifetech\u2019s post\u2011IPO growth trajectory, market share expansion in cardiovascular imaging, and international regulatory progress. Actual results may differ due to competitive responses from multinational device manufacturers, pricing pressure from national procurement programs, and execution risks in manufacturing scale\u2011up.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Insight Lifetech, a Qiming Venture Partners\u2011backed innovative medical device manufacturer, has listed on the Shanghai&#8230;<\/p>\n","protected":false},"author":1,"featured_media":56556,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[3530,72,4597],"class_list":["post-56555","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-insight-lifetech","tag-ipo","tag-sha-688712"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Insight Lifetech, a Qiming Venture Partners\u2011backed innovative medical device manufacturer, has listed on the Shanghai Stock Exchange&#039;s STAR Market (SHA: 688712), pricing its IPO at RMB\u202f17.52 (USD\u202f2.52) per share and achieving a market capitalization of RMB\u202f20.98 billion (USD\u202f3.02 billion) based on its opening price of RMB\u202f50.31 (USD\u202f7.24). The debut marks a milestone for China\u2019s domestic precision cardiovascular interventional technology sector.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56555\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging\" \/>\n<meta property=\"og:description\" content=\"Insight Lifetech, a Qiming Venture Partners\u2011backed innovative medical device manufacturer, has listed on the Shanghai Stock Exchange&#039;s STAR Market (SHA: 688712), pricing its IPO at RMB\u202f17.52 (USD\u202f2.52) per share and achieving a market capitalization of RMB\u202f20.98 billion (USD\u202f3.02 billion) based on its opening price of RMB\u202f50.31 (USD\u202f7.24). The debut marks a milestone for China\u2019s domestic precision cardiovascular interventional technology sector.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56555\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-06T14:30:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-06T14:30:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0610.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56555#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56555\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging\",\"datePublished\":\"2026-02-06T14:30:29+00:00\",\"dateModified\":\"2026-02-06T14:30:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56555\"},\"wordCount\":487,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56555#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0610.webp\",\"keywords\":[\"Insight Lifetech\",\"IPO\",\"SHA: 688712\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56555#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56555\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56555\",\"name\":\"Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56555#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56555#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0610.webp\",\"datePublished\":\"2026-02-06T14:30:29+00:00\",\"dateModified\":\"2026-02-06T14:30:30+00:00\",\"description\":\"Insight Lifetech, a Qiming Venture Partners\u2011backed innovative medical device manufacturer, has listed on the Shanghai Stock Exchange's STAR Market (SHA: 688712), pricing its IPO at RMB\u202f17.52 (USD\u202f2.52) per share and achieving a market capitalization of RMB\u202f20.98 billion (USD\u202f3.02 billion) based on its opening price of RMB\u202f50.31 (USD\u202f7.24). The debut marks a milestone for China\u2019s domestic precision cardiovascular interventional technology sector.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56555#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56555\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56555#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0610.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0610.webp\",\"width\":1080,\"height\":608,\"caption\":\"Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56555#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging - Insight, China&#039;s Pharmaceutical Industry","description":"Insight Lifetech, a Qiming Venture Partners\u2011backed innovative medical device manufacturer, has listed on the Shanghai Stock Exchange's STAR Market (SHA: 688712), pricing its IPO at RMB\u202f17.52 (USD\u202f2.52) per share and achieving a market capitalization of RMB\u202f20.98 billion (USD\u202f3.02 billion) based on its opening price of RMB\u202f50.31 (USD\u202f7.24). The debut marks a milestone for China\u2019s domestic precision cardiovascular interventional technology sector.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56555","og_locale":"en_US","og_type":"article","og_title":"Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging","og_description":"Insight Lifetech, a Qiming Venture Partners\u2011backed innovative medical device manufacturer, has listed on the Shanghai Stock Exchange's STAR Market (SHA: 688712), pricing its IPO at RMB\u202f17.52 (USD\u202f2.52) per share and achieving a market capitalization of RMB\u202f20.98 billion (USD\u202f3.02 billion) based on its opening price of RMB\u202f50.31 (USD\u202f7.24). The debut marks a milestone for China\u2019s domestic precision cardiovascular interventional technology sector.","og_url":"https:\/\/flcube.com\/?p=56555","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-06T14:30:29+00:00","article_modified_time":"2026-02-06T14:30:30+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0610.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56555#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56555"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging","datePublished":"2026-02-06T14:30:29+00:00","dateModified":"2026-02-06T14:30:30+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56555"},"wordCount":487,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=56555#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0610.webp","keywords":["Insight Lifetech","IPO","SHA: 688712"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56555#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56555","url":"https:\/\/flcube.com\/?p=56555","name":"Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=56555#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=56555#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0610.webp","datePublished":"2026-02-06T14:30:29+00:00","dateModified":"2026-02-06T14:30:30+00:00","description":"Insight Lifetech, a Qiming Venture Partners\u2011backed innovative medical device manufacturer, has listed on the Shanghai Stock Exchange's STAR Market (SHA: 688712), pricing its IPO at RMB\u202f17.52 (USD\u202f2.52) per share and achieving a market capitalization of RMB\u202f20.98 billion (USD\u202f3.02 billion) based on its opening price of RMB\u202f50.31 (USD\u202f7.24). The debut marks a milestone for China\u2019s domestic precision cardiovascular interventional technology sector.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56555#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56555"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=56555#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0610.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0610.webp","width":1080,"height":608,"caption":"Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56555#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0610.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56555","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56555"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56555\/revisions"}],"predecessor-version":[{"id":56557,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56555\/revisions\/56557"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/56556"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56555"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56555"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56555"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}